Sequence: AGYLLGKINLKALAALAKKIL
| Experiment Id | EXP001472 |
|---|---|
| Paper | Cell-Penetrating Peptide and siRNA-Mediated Therapeutic Effects on Endometriosis and Cancer In Vitro |
| Peptide | PepFect6 (PF6) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Set by molar ratio 40 (CPP:siRNA). Exact µM peptide depends on siRNA concentration. |
| Rna Concentration | 2D primary cells: 100 nM siRNA final in medium |
| Mixing Ratio | CPP/siRNA NPs formed at molar ratio 40 (CPP:siRNA) by mixing peptide + siRNA in MilliQ water (pH 5.3–6.3) and incubating 45 min at room temperature before transfection. |
| Formulation Format | CPP/siRNA nanoparticles (noncovalent electrostatic NPs) |
| Formulation Components | PepFect6 (PF6) + siVEGF |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Primary human endometriotic stromal cells (peritoneal + ovarian lesions; 2D cultures) |
| Animal Model | |
| Administration Route | |
| Output Type | Functional RNA effect: VEGF knockdown (qRT-PCR, 48 h) and reduced invasion (Matrigel). |
| Output Value | |
| Output Units | |
| Output Notes | PF6/siVEGF induced significant VEGF knockdown in endometriotic stromal cells and reduced invasion compared to controls. Reported (from prior characterizations): ~30–40 nm (TEM) and ~100–200 nm (DLS) when complexed with siRNA (not newly measured in this paper). |
| Toxicity Notes | Authors reference prior cytotoxicity characterization for PF6/NF70 at similar conditions; current work focuses on knockdown and phenotypic assays (migration/invasion/proliferation). |
| Curation Notes |